Session date: 
Wednesday, December 7, 2016 - 7:00am to 8:00am
Location: 
Eye Institute
925 N. 87th St.
Lower Level Conference Room
Milwaukee, WI 53226
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

Systemic medications, particularly hydroxyl Chloroquine have the potential to cause retinal toxicity. We will review some of those medications and present two new medications for consideration. We’ll then review strategies for surveillance and management of toxicities.  

Advanced in clinical and bench research in ophthalmology has produced multiple new treatment options for a variety of ocular diseases.  New technology, including the fast growing field of ocular imaging, is been used to further understand eye anatomy and pathology.  Progress in the field of ocular surgery has introduced new techniques and better outcomes.  The clinical and research environment is complex; issues related to ethics, quality improvement and new technology affect all eye care providers. The Eye Institute has, as one of its mission, the goal of being at the forefront of research, clinical care and education.  Our goal is to educate the academic and community eye care providers, residents, researchers and medical students on the best and newest clinical and surgical treatments, cutting edge research and important non-clinical topics available in the field.

 
Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
AMA Credit Designation:
The Medical College of Wisconsin designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Hours of Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this activity for up to 1.00 hours of participation for continuing education for allied health professionals
Target audience: 
  • Community eye care professionals
  • Full time faculty
  • Residents
  • Fellow ophthalmologists
  • Optometrists
  • Ophthalmic photographers
Learning objectives: 

At the conclusion of this activity, I will be able to:

  1. Review systemic medications that may be associated with Retinal Toxicity
  2. Describe ophthalmic testing and abnormalities seen with toxicity
  3. Review toxicity surveillance strategies – particularly for HydroxyChloroquine
Faculty & credentials: 
Activity Directors:
William J. Wirostko, MD
 
Speaker:

Thomas B. Connor, Jr., MD
Professor of Ophthalmology & Visual Sciences
Medical College of Wisconsin

All persons in control of content has no relevant financial relationships to disclose with the exception of the following persons;
 
N/A

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

CME Coordinator Contact Information

Name: 
Mary Schafer
Phone number: 
+1 (414) 955-7840